Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L W Moreland

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Rheumatic Diseases Clinics of North America|June 9, 2001
Potential biologic agents for treating rheumatoid arthritisL W Moreland
The Journal of Rheumatology. Supplement|May 18, 1999
Inhibitors of tumor necrosis factor for rheumatoid arthritisL W Moreland
The Journal of Rheumatology. Supplement|March 1, 1996
Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritisL W Moreland
Expert Opinion on Investigational Drugs|July 5, 2005
Clinical and pharmacological experience with etanerceptL W Moreland
Bulletin on the Rheumatic Diseases|June 1, 1996
Spinal stenosisL W Moreland
Drugs of Today (Barcelona, Spain : 1998)|September 16, 2003
The role of cytokines in rheumatoid arthritis: inhibition of cytokines in therapeutic trialsL W Moreland
The Israel Medical Association Journal : IMAJ|September 29, 2001
Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritisL W Moreland
Cleveland Clinic Journal of Medicine|June 22, 1999
Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritisL W Moreland
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Recent advances in anti-tumour necrosis factor (TNF) therapy in rheumatoid arthritis: focus on the soluble TNF receptor p75 fusion protein, etanerceptL W Moreland
Rheumatic Diseases Clinics of North America|August 26, 1998
Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritisL W Moreland
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Rheumatic Diseases Clinics of North America|June 9, 2001
Potential biologic agents for treating rheumatoid arthritisL W Moreland
The Journal of Rheumatology. Supplement|May 18, 1999
Inhibitors of tumor necrosis factor for rheumatoid arthritisL W Moreland
The Journal of Rheumatology. Supplement|March 1, 1996
Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritisL W Moreland
Expert Opinion on Investigational Drugs|July 5, 2005
Clinical and pharmacological experience with etanerceptL W Moreland
Bulletin on the Rheumatic Diseases|June 1, 1996
Spinal stenosisL W Moreland
Drugs of Today (Barcelona, Spain : 1998)|September 16, 2003
The role of cytokines in rheumatoid arthritis: inhibition of cytokines in therapeutic trialsL W Moreland
The Israel Medical Association Journal : IMAJ|September 29, 2001
Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritisL W Moreland
Cleveland Clinic Journal of Medicine|June 22, 1999
Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritisL W Moreland
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 23, 2007
Recent advances in anti-tumour necrosis factor (TNF) therapy in rheumatoid arthritis: focus on the soluble TNF receptor p75 fusion protein, etanerceptL W Moreland
Rheumatic Diseases Clinics of North America|August 26, 1998
Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritisL W Moreland
Pageof 10